Some fair points R-7! You've summarised it perfectly with 'We are strengthening our platform'. This is exactly what is happening and is nicely exemplified in the Q3 animal testing of naive exosomes produced by LEAP. FRCBS would have likely animal tested (blood cell derived) naive exosomes and been satisfied with the safety results such that they're now exploring ongoing usage of LEAP ... Exopharm would be seeking to run similar tests and share the results to excite potential future partners and therefore expedite licencing deals. Very smart move from the Exopharm team.
Some fair points R-7! You've summarised it perfectly with 'We...
Add EX1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.933M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| EX1 (ASX) Chart |
Day chart unavailable